Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician

Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P. Abraham

Research output: Contribution to journalReview articlepeer-review


Several biologic therapies have been approved for enteric diseases. We evaluate each biologic’s role based on their mechanism of action in treating these conditions. This review examines data on efficacy and safety, as well as considerations for using these therapies in clinical practice in inflammatory bowel diseases, enteric infections—specifically Clostridioides difficile colitis—and potentially in the increasingly prevalent disorder of eosinophilic esophagitis. When choosing an appropriate therapy, it is important to assess patient severity, as most biologics are approved for those with moderate to severe disease activity. With many years of data from clinical trials and real-world experience, these therapies have been shown to improve outcomes overall in enteric diseases, contributing to more options for our patients.

Original languageEnglish (US)
Pages (from-to)67-83
Number of pages17
JournalBiologics: Targets and Therapy
StatePublished - 2022


  • Clostridioides difficile colitis
  • Crohn’s disease
  • biologics
  • enteric disease
  • microscopic colitis
  • ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)


Dive into the research topics of 'Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician'. Together they form a unique fingerprint.

Cite this